New York State Teachers Retirement System Buys 500 Shares of Harmony Biosciences Holdings, Inc. $HRMY

New York State Teachers Retirement System lifted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report) by 1.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,293 shares of the company’s stock after purchasing an additional 500 shares during the quarter. New York State Teachers Retirement System owned 0.06% of Harmony Biosciences worth $1,020,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in HRMY. New Vernon Capital Holdings II LLC grew its holdings in shares of Harmony Biosciences by 3,219.0% during the 1st quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock valued at $16,211,000 after purchasing an additional 473,708 shares during the last quarter. LSV Asset Management grew its holdings in shares of Harmony Biosciences by 25.0% during the 1st quarter. LSV Asset Management now owns 1,194,961 shares of the company’s stock valued at $39,661,000 after purchasing an additional 238,744 shares during the last quarter. Allianz Asset Management GmbH boosted its position in Harmony Biosciences by 1,709.0% during the 1st quarter. Allianz Asset Management GmbH now owns 220,704 shares of the company’s stock worth $7,325,000 after buying an additional 208,504 shares during the period. American Century Companies Inc. boosted its position in Harmony Biosciences by 16.9% during the 1st quarter. American Century Companies Inc. now owns 1,288,787 shares of the company’s stock worth $42,775,000 after buying an additional 186,183 shares during the period. Finally, Woodline Partners LP acquired a new stake in Harmony Biosciences during the 1st quarter worth approximately $6,035,000. 86.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Harmony Biosciences in a research report on Tuesday, October 14th. Mizuho cut their target price on shares of Harmony Biosciences from $50.00 to $35.00 and set an “outperform” rating on the stock in a research report on Thursday, September 25th. UBS Group cut their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.56.

Get Our Latest Research Report on HRMY

Harmony Biosciences Stock Up 0.4%

Shares of NASDAQ HRMY opened at $26.27 on Thursday. The company has a market capitalization of $1.51 billion, a P/E ratio of 8.47, a price-to-earnings-growth ratio of 0.32 and a beta of 0.79. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $41.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The company’s 50 day moving average price is $31.72 and its 200-day moving average price is $32.55.

Harmony Biosciences (NASDAQ:HRMYGet Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

See Also

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYFree Report).

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.